RE:RE:Oncopeptide The late stage patients progressively have more sortilin expression which is the key to the MOA of their PDC. They need those receptors to bind their molecules to and get into cancer cells so what Oncopeptide was trying to do was to move to earlier stages of cancer thus bigger market with the same therapeutic window resulting in serious adverse effects so my point is although we want as much as possible of the cancer agent into cancer cells they need to be careful deciding their dosing as it can backfire later on when the try the drug on bigger groups of patients.
PWIB123 wrote: I'm trying to keep up and learn alongside where you all see risk. What stage were these guys in when they pulled the plug? Are you saying that because we are treating people who are further advanced in cancer stage that we have better odds of avoiding the Oncopeptide demise?